Tim Kutzkey - Apr 4, 2024 Form 4 Insider Report for Surrozen, Inc./DE (SRZN)

Role
Director, 10%+ Owner
Signature
/s/James Evangelista, as attorney-in-fact for Tim Kutzkey
Stock symbol
SRZN
Transactions as of
Apr 4, 2024
Transactions value $
$2,999,994
Form type
4
Date filed
4/8/2024, 04:24 PM
Previous filing
May 19, 2023
Next filing
Jun 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRZN Common Stock Purchase $1.41M +90.9K +44.59% $15.50 295K Apr 4, 2024 By The Column Group III, LP F1, F2
transaction SRZN Common Stock Purchase $1.59M +103K +44.59% $15.50 333K Apr 4, 2024 By The Column Group III-A, LP F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRZN Series A Common Warrants Purchase +90.9K 90.9K Apr 4, 2024 Common Stock 90.9K $15.50 By The Column Group III, LP F1, F2, F4
transaction SRZN Series A Common Warrants Purchase +103K 103K Apr 4, 2024 Common Stock 103K $15.50 By The Column Group III-A, LP F1, F3, F4
transaction SRZN Series B Common Warrants Purchase +98.9K 98.9K Apr 4, 2024 Common Stock 98.9K $14.25 By The Column Group III, LP F1, F2, F5
transaction SRZN Series B Common Warrants Purchase +112K 112K Apr 4, 2024 Common Stock 112K $14.25 By The Column Group III-A, LP F1, F3, F5
transaction SRZN Series C Common Warrants Purchase +352K 352K Apr 4, 2024 Common Stock 352K $16.00 By The Column Group III, LP F1, F2, F6
transaction SRZN Series C Common Warrants Purchase +398K 398K Apr 4, 2024 Common Stock 398K $16.00 By The Column Group III-A, LP F1, F3, F6
transaction SRZN Series D Common Warrants Purchase +352K 352K Apr 4, 2024 Common Stock 352K $16.00 By The Column Group III, LP F1, F2, F7
transaction SRZN Series D Common Warrants Purchase +398K 398K Apr 4, 2024 Common Stock 398K $16.00 By The Column Group III-A, LP F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.
F2 The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F3 The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F4 These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.
F5 These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.
F6 These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).
F7 These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).